TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON

2016123 citationsJournal Article

Authors

Jean-François H. Geschwind · Johns Hopkins University

Masatoshi Kudo · Johns Hopkins University

Jorge A. Marrero · Johns Hopkins University

Alan P. Venook · Johns Hopkins University

Xiao-Ping Chen · Tongji University

Jean-Pierre Bronowicki · Johns Hopkins University

Lucy Dagher ·

Abstract

Global variation exists in TACE use in sorafenib-treated HCC patients. The combination of TACE with sorafenib appears to be a well-tolerated and viable therapeutic approach.

Topics & Keywords

Hepatocellular Carcinoma Treatment and Prognosis Cancer Mechanisms and Therapy Hepatitis C virus research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Radiology

Volume 279, Issue 2, pp. 630-640

DOI: 10.1148/radiol.2015150667

Field-Weighted Citation Impact: 10.71